Altimmune, Inc. (ALT) Reaches $0.93 52-Week Low; Pimco Municipal Income Fund III (PMX) Sentiment Is 2.4

April 7, 2018 - By Vivian Currie

The stock of Altimmune, Inc. (NASDAQ:ALT) hit a new 52-week low and has $0.87 target or 6.00% below today’s $0.93 share price. The 6 months bearish chart indicates high risk for the $16.81 million company. The 1-year low was reported on Apr, 7 by Barchart.com. If the $0.87 price target is reached, the company will be worth $1.01 million less. The stock decreased 2.26% or $0.0215 during the last trading session, reaching $0.9285. About 375,367 shares traded or 36.66% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 84.57% since April 7, 2017 and is downtrending. It has underperformed by 96.12% the S&P500.

Pimco Municipal Income Fund III (PMX) investors sentiment increased to 2.4 in Q4 2017. It’s up 1.27, from 1.13 in 2017Q3. The ratio has improved, as 12 investment managers increased or started new positions, while 5 reduced and sold their stock positions in Pimco Municipal Income Fund III. The investment managers in our database now own: 1.00 million shares, up from 879,983 shares in 2017Q3. Also, the number of investment managers holding Pimco Municipal Income Fund III in top ten positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 3 Increased: 6 New Position: 6.

The stock increased 0.35% or $0.04 during the last trading session, reaching $11.4. About 58,172 shares traded. PIMCO Municipal Income Fund III (PMX) has declined 1.40% since April 7, 2017 and is downtrending. It has underperformed by 12.95% the S&P500.

Benjamin F. Edwards & Company Inc. holds 0.09% of its portfolio in PIMCO Municipal Income Fund III for 70,682 shares. Segment Wealth Management Llc owns 13,000 shares or 0.04% of their US portfolio. Moreover, M&R Capital Management Inc has 0.03% invested in the company for 12,000 shares. The Oklahoma-based Bokf Na has invested 0.02% in the stock. First Foundation Advisors, a California-based fund reported 23,979 shares.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $16.81 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Altimmune, Inc. (NASDAQ:ALT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: